Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 57,129
  • Shares Outstanding, K 90,681
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,043 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 28.26
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.02 on 11/26/25
  • Next Earnings Date 05/26/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.570 +14.04%
on 03/30/26
0.670 -2.99%
on 04/13/26
+0.050 (+8.33%)
since 03/13/26
3-Month
0.570 +14.04%
on 03/30/26
0.700 -7.14%
on 02/03/26
+0.030 (+4.84%)
since 01/14/26
52-Week
0.570 +14.04%
on 03/30/26
1.140 -42.98%
on 09/16/25
-0.040 (-5.80%)
since 04/11/25

Most Recent Stories

More News
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”)...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90)  (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Announces Corporate Updates

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today announced changes to its board...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today announced new laboratory data...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-biotechnology company...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing...

See More

Key Turning Points

3rd Resistance Point 0.677
2nd Resistance Point 0.663
1st Resistance Point 0.657
Last Price 0.650
1st Support Level 0.637
2nd Support Level 0.623
3rd Support Level 0.617

See More

52-Week High 1.140
Fibonacci 61.8% 0.922
Fibonacci 50% 0.855
Fibonacci 38.2% 0.788
Last Price 0.650
52-Week Low 0.570

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.